Yao Wei, Lane Nancy E
Center for Musculoskeletal Health, University of California at Davis School of Medicine, Sacramento, CA 95817, USA.
Center for Musculoskeletal Health, University of California at Davis School of Medicine, Sacramento, CA 95817, USA.
Bone. 2015 Jan;70:62-5. doi: 10.1016/j.bone.2014.07.026. Epub 2014 Aug 28.
Osteoporosis is a disease of excess skeletal fragility that results from estrogen loss and aging. Age related bone loss has been attributed to both elevated bone resorption and insufficient bone formation. We developed a hybrid compound, LLP2A-Ale in which LLP2A has high affinity for the α4β1 integrin on mesenchymal stem cells (MSCs) and alendronate has high affinity for bone. When LLP2A-Ale was injected into mice, the compound directed MSCs to both trabecular and cortical bone surfaces and increased bone mass and bone strength. Additional studies are underway to further characterize this hybrid compound, LLP2A-Ale, and how it can be utilized for the treatment of bone loss resulting from hormone deficiency, aging, and inflammation and to augment bone fracture healing. This article is part of a Special Issue entitled "Stem Cells and Bone".
骨质疏松症是一种因雌激素丧失和衰老导致骨骼过度脆弱的疾病。与年龄相关的骨质流失被认为是由于骨吸收增加和骨形成不足所致。我们研发了一种混合化合物LLP2A-Ale，其中LLP2A对间充质干细胞（MSC）上的α4β1整合素具有高亲和力，而阿仑膦酸钠对骨骼具有高亲和力。当将LLP2A-Ale注射到小鼠体内时，该化合物可引导MSC到达小梁骨和皮质骨表面，并增加骨量和骨强度。正在进行进一步的研究，以更全面地描述这种混合化合物LLP2A-Ale，以及它如何用于治疗由激素缺乏、衰老和炎症引起的骨质流失，并促进骨折愈合。本文是名为“干细胞与骨骼”的特刊的一部分。
